A5100747744- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research and Treatments
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Neurological Disease Mechanisms and Treatments
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Advanced Glycation End Products research
- Chronic Lymphocytic Leukemia Research
- Acute Kidney Injury Research
- Colorectal Cancer Screening and Detection
- Atmospheric chemistry and aerosols
- Cancer Mechanisms and Therapy
- Sarcoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Chronic Kidney Disease and Diabetes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Traditional Chinese Medicine Analysis
- Renal cell carcinoma treatment
- Orthodontics and Dentofacial Orthopedics
Jiangsu Hengrui Medicine (China)
2019-2023
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
Hebei Medical University
2014-2023
Sun Yat-sen University
2023
Shaanxi University of Chinese Medicine
2023
Chengdu University
2022
Sichuan University
2022
Hengshui University
2021
State Key Laboratory of Kidney Diseases
2018-2019
Chinese PLA General Hospital
2018-2019
Abstract Background Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common event related to camrelizumab, an immune checkpoint inhibitor, but lack comprehensive analyses. In this study, we conducted analyses on RCCEP in advanced hepatocellular carcinoma (HCC) patients treated camrelizumab monotherapy. Methods Data were derived from a Chinese nationwide, multicenter phase 2 trial...
Abstract Purpose: Capecitabine plus oxaliplatin (CAPOX) is one of the standard first-line treatments for unresectable, advanced, or metastatic gastric gastroesophageal junction (G/GEJ) adenocarcinoma. Camrelizumab shows promising antitumor activity in advanced G/GEJ adenocarcinoma a phase I study. We reported outcomes cohort 1 multicenter, open-label, II trial, which assessed camrelizumab combination with CAPOX followed by apatinib as regimen Patients and Methods: Systemic treatment-naïve...
Background Emerging clinical data suggest that an immune checkpoint inhibitor in combination with antiangiogenic agent is a reasonable strategy for multiple malignancies. We assessed the of camrelizumab apatinib pretreated advanced primary liver cancer (PLC, cohort A) from multicohort phase Ib/II trial. Methods Patients PLC after prior systemic treatment(s) were administered (3 mg/kg, once every 2 weeks) plus (125, 250, 375, or 500 mg; per day) 3+3 dose-escalation stage and subsequent...
4074 Background: Advanced hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) patients (pts) have very limited treatment options. Considering the immunogenic effects of oxaliplatin, combination camrelizumab with oxaliplatin-based chemotherapy might bring a better clinical benefit. Methods: That was an ongoing single-arm, multicenter phase 2 trial. HCC or BTC pts naive to systemic were given (3 mg/kg i.v., every weeks) plus typical FOLFOX4 (infusional fluorouracil, leucovorin...
Biliary tract cancer (BTC) is a highly malignant tumor with limited treatment options and poor prognosis. Our study aimed to evaluate camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced BTC. In this multicenter, open-label, phase 2 trial conducted in China (ClinicalTrials.gov, NCT03092895), untreated patients BTC were given (3 mg/kg iv drip injection, every weeks) typical FOLFOX4 (Cam-FOLFOX4 group; infusional 5-fluorouracil, leucovorin oxaliplatin) or GEMOX...
Abstract Purpose: Patients with recurrent or metastatic cervical cancer have limited treatment options after platinum-containing treatment. We initiated a phase I study to assess SHR-1701, novel bifunctional fusion protein composed of mAb against programmed death ligand 1 (PD-L1) fused the extracellular domain TGFβ receptor II, in solid tumors (NCT03774979). Here, results from cohort are presented. and Methods: who progressed during platinum-based therapy were enrolled receive SHR-1701 at 30...
Abstract Background Dual inhibition of PD-1/PD-L1 and TGF-β pathways is a rational therapeutic strategy for malignancies. SHR-1701 new bifunctional fusion protein composed monoclonal antibody against PD-L1 fused with the extracellular domain receptor II. This first-in-human trial aimed to assess in pretreated advanced solid tumors find population who could benefit from SHR-1701. Methods was dose-escalation, dose-expansion, clinical-expansion phase 1 study. Dose escalation initiated by...
NASH is a highly prevalent metabolic syndrome that has no specific approved agents up to now. BBBP, which mainly contains bile acids, possess various pharmacological properties and some acids are available for treatment. Herein, the therapeutic effects underlying mechanisms of BBBP against were systemically evaluated. In this study, mice received an HFHS diet over 20-week period induce with or without intervention used evaluate effect NASH. Our results demonstrated attenuated hepatic...
The non-neuronal and non-muscular effects of botulinum toxin type A (BTXA) on scar reduction has been discovered. This study was designed to investigate the BTXA macrophages polarization during early stage skin repair. defect model established dorsal SD rats. intracutaneous injected into edge wound immediately as established. Histological examinations were performed samples. Raw 264.7 selected cell recruited circulating macrophages, induced for M1 by LPS. Identify signaling pathways that...
In search of novel anti-ischemic stroke agents with higher potency than a known drug 3-n-butylphthalide (NBP), series hybrids ((S)- and (R)-5a–f) from optically active ring-opened NBP derivative isosorbide were synthesized for evaluating their activity. Compound (S)-5e displayed the strongest activity in inhibiting adenosine diphosphate (ADP) arachidonic acid (AA)-induced platelet aggregation vitro, 10.0- 8.4-fold more effectiveness (S)-NBP, respectively. Furthermore, was stable artificial...
Immune checkpoint inhibitors and chemotherapy can synergistically increase efficacy in a variety of malignancies. We conducted this phase Ib/II study to assess the safety anti-PD-1 antibody camrelizumab combination with FOLFOX4 for treatment-naive advanced hepatocellular carcinoma (aHCC).
Organic aerosols will likely form in semisolid, glassy, and high viscous state the atmosphere, which show nonequilibrium kinetic characteristics at low relative humidity (RH) conditions. In this study, we applied optical tweezers to investigate water transport a sucrose/(NH4)2SO4 droplet with organic inorganic mole ratio (OIR). The characteristic time between radius RH was used describe mass transfer difference dependent on RH. For OIR greater than 1:1 droplets, (<∼30% RH) two orders...
In a multicenter, open-label, parallel-group, randomized, phase 2 study for pretreated advanced hepatocellular carcinoma (HCC), camrelizumab showed potent antitumor activity and acceptable safety profile. The aim of this report was to provide long-term data evaluate potential benefit treatment with beyond progression.From November 15, 2016, 16, 2017, 217 patients received 3 mg/kg intravenously every or weeks. Treatment first Response Evaluation Criteria in Solid Tumors (RECIST)-defined...
9055 Background: Despite the development of targeted therapies for advanced NSCLC harboring EGFR mutations ( EGFR+), acquired resistance remains inevitable. Immune checkpoint inhibitor as monotherapy has limited efficacy. Blockade TGF-β pathway which plays a key role in immune suppression may enhance tumor response to anti-PD-1/PD-L1 antibodies. Here, we assessed SHR-1701, novel bifunctional fusion protein composed mAb against PD-L1 fused with extracellular domain receptor II, pts including...
2503 Background: Dual inhibition of PD-1/PD-L1 and TGF-β pathways is a promising therapeutic strategy for multiple tumor types. SHR-1701 novel bifunctional anti-PD-L1/TGF-βRII agent. This dose escalation expansion phase 1 study aimed to evaluated the safety preliminary anti-tumor acitivity in refractory solid tumors. Methods: The period was initiated by accelerated titration (1 mg/kg Q3W) then switched 3+3 scheme (3, 10, 20, 30 Q3W Q2W). expanded at doses Q2W. primary objectives were...
Abstract Purpose To explore the potential causal links between obesity, type 2 diabetes (T2D), and lifestyle choices (such as smoking, alcohol coffee consumption, vigorous physical activity) on stress urinary incontinence (SUI), this study employs a Mendelian Randomization approach. This research aims to clarify these associations, which have been suggested but not conclusively established in prior observational studies. Methods Genetic instruments associated with exposures at genome‐wide...
The inflammatory response mediated by microglia plays a critical role in the progression of ischemic stroke. Phosphoinositide 3-kinase gamma (PI3Kγ) has been implicated multiple and autoimmune diseases, making it promising target for therapeutic intervention. aim this study was to evaluate efficacy 8e, hydrogen sulfide (H₂S) releasing derivative 3-n-butylphthalide (NBP), on brain damage PI3Kγ signaling following cerebral ischemia injury. 8e significantly reduced sensorimotor deficits, focal...
Introduction The mechanism of the immediate adverse drug reactions (ADRs) induced by ShenMai injection (SMI) has not been completely elucidated. Within 30 minutes, ears and lungs mice injected with SMI for first time showed edema exudation reactions. These were different from IV hypersensitivity. theory pharmacological interaction immune receptor (p-i) offered a new insight into mechanisms ADRs SMI. Methods In this study, we determined that mediated thymus-derived T cells through BALB/c...
4031 Background: Capecitabine plus oxaliplatin (CAPOX) is one of the standard first-line treatments for advanced or metastatic gastric cancer. Camrelizumab (SHR-1210, an anti–PD-1 antibody) shows promising anti-tumor activity in patients (pts) with gastroesophageal junction (G/GEJ) combined CAPOX untreated G/GEJ cancer was assessed as a part ongoing multicenter, open-label phase 2 trial (cohort 1), and encouraging preliminary results were reported. Here, we present updated safety efficacy...